Literature DB >> 28916238

Association of midlife lipids with 20-year cognitive change: A cohort study.

Melinda C Power1, Andreea Rawlings2, A Richey Sharrett2, Karen Bandeen-Roche3, Josef Coresh4, Christie M Ballantyne5, Yashashwi Pokharel6, Erin D Michos7, Alan Penman8, Alvaro Alonso9, David Knopman10, Thomas H Mosley11, Rebecca F Gottesman12.   

Abstract

INTRODUCTION: Existing studies predominantly consider the association of late-life lipid levels and subsequent cognitive change. However, midlife rather than late-life risk factors are often most relevant to cognitive health.
METHODS: We quantified the association between measured serum lipids in midlife and subsequent 20-year change in performance on three cognitive tests in 13,997 participants of the Atherosclerosis Risk in Communities study.
RESULTS: Elevated total cholesterol, low-density lipoprotein cholesterol, and triglycerides were associated with greater 20-year decline on a test of executive function, sustained attention, and processing speed. Higher total cholesterol and triglycerides were also associated with greater 20-year decline in memory scores and a measure summarizing performance on all three tests. High-density lipoprotein cholesterol was not associated with cognitive change. Results were materially unchanged in sensitivity analyses addressing informative missingness. DISCUSSION: Elevated total cholesterol, low-density lipoprotein cholesterol, and triglycerides in midlife were associated with greater 20-year cognitive decline.
Copyright © 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cholesterol; Cognition; Cognitive change; Cognitive decline; Cohort; Dementia; Epidemiology; Lipids; Longitudinal

Mesh:

Substances:

Year:  2017        PMID: 28916238      PMCID: PMC5803364          DOI: 10.1016/j.jalz.2017.07.757

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  41 in total

1.  A dual-precipitation method evaluated for measurement of cholesterol in high-density lipoprotein subfractions HDL2 and HDL3 in human plasma.

Authors:  W Patsch; S A Brown; J D Morrisett; A M Gotto; J R Patsch
Journal:  Clin Chem       Date:  1989-02       Impact factor: 8.327

2.  Lower serum cholesterol level and later decline in cognitive function in older people living in the community, Japan.

Authors:  T Wada; K Matsubayashi; K Okumiya; S Kimura; Y Osaka; Y Doi; T Ozawa
Journal:  J Am Geriatr Soc       Date:  1997-11       Impact factor: 5.562

3.  Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease.

Authors:  I L Notkola; R Sulkava; J Pekkanen; T Erkinjuntti; C Ehnholm; P Kivinen; J Tuomilehto; A Nissinen
Journal:  Neuroepidemiology       Date:  1998       Impact factor: 3.282

Review 4.  Statins, cognition, and dementia—systematic review and methodological commentary.

Authors:  Melinda C Power; Jennifer Weuve; A Richey Sharrett; Deborah Blacker; Rebecca F Gottesman
Journal:  Nat Rev Neurol       Date:  2015-03-24       Impact factor: 42.937

5.  Impact of plasma lipids and time on memory performance in healthy elderly without dementia.

Authors:  C Reitz; J Luchsinger; M-X Tang; J Manly; R Mayeux
Journal:  Neurology       Date:  2005-04-26       Impact factor: 9.910

6.  Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study.

Authors:  S Kalmijn; D Foley; L White; C M Burchfiel; J D Curb; H Petrovitch; G W Ross; R J Havlik; L J Launer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-10       Impact factor: 8.311

7.  The 32-year relationship between cholesterol and dementia from midlife to late life.

Authors:  M M Mielke; P P Zandi; H Shao; M Waern; S Östling; X Guo; C Björkelund; L Lissner; I Skoog; D R Gustafson
Journal:  Neurology       Date:  2010-11-10       Impact factor: 9.910

Review 8.  Dyslipidemia and the risk of Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

9.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

Review 10.  Guidelines for reporting methodological challenges and evaluating potential bias in dementia research.

Authors:  Jennifer Weuve; Cécile Proust-Lima; Melinda C Power; Alden L Gross; Scott M Hofer; Rodolphe Thiébaut; Geneviève Chêne; M Maria Glymour; Carole Dufouil
Journal:  Alzheimers Dement       Date:  2015-09       Impact factor: 21.566

View more
  27 in total

1.  Plasma phospholipid very-long-chain SFAs in midlife and 20-year cognitive change in the Atherosclerosis Risk in Communities (ARIC): a cohort study.

Authors:  Danni Li; Jeffrey R Misialek; Ma Jing; Michael Y Tsai; John H Eckfeldt; Lyn M Steffen; David Knopman; Lisa Wruck; Rebecca Gottesman; Tom H Mosley; A Richey Sharrett; Alvaro Alonso
Journal:  Am J Clin Nutr       Date:  2020-06-01       Impact factor: 7.045

2.  High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change.

Authors:  Yashashwi Pokharel; Farah Mouhanna; Andrea L C Schneider; Andreea M Rawlings; David S Knopman; Vijay Nambi; Salim S Virani; Ron C Hoogeveen; Alvaro Alonso; Gerardo Heiss; Josef Coresh; Thomas Mosley; Rebecca Gottesman; Elizabeth Selvin; Christie Ballantyne; Melinda C Power
Journal:  J Am Geriatr Soc       Date:  2019-07-30       Impact factor: 5.562

3.  Genetic Interaction with Plasma Lipids on Alzheimer's Disease in the Framingham Heart Study.

Authors:  Gina M Peloso; Alexa S Beiser; Anita L Destefano; Sudha Seshadri
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 4.  Nutrition and Metabolic Profiles in the Natural History of Dementia: Recent Insights from Systems Biology and Life Course Epidemiology.

Authors:  Sophie Lefèvre-Arbogast; Maude Wagner; Cécile Proust-Lima; Cécilia Samieri
Journal:  Curr Nutr Rep       Date:  2019-09

5.  Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: The Atherosclerosis Risk in Communities Study.

Authors:  David S Knopman; Rebecca F Gottesman; A Richey Sharrett; Amanda L Tapia; Sonia DavisThomas; B Gwen Windham; Laura Coker; Andrea L C Schneider; Alvaro Alonso; Josef Coresh; Marilyn S Albert; Thomas H Mosley
Journal:  Alzheimers Dement       Date:  2018-05-12       Impact factor: 21.566

6.  ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.

Authors:  Yashashwi Pokharel; Farah Mouhanna; Vijay Nambi; Salim S Virani; Ron Hoogeveen; Alvaro Alonso; Gerardo Heiss; Josef Coresh; Thomas Mosley; Rebecca F Gottesman; Christie M Ballantyne; Melinda C Power
Journal:  Neurology       Date:  2019-05-01       Impact factor: 9.910

7.  Systemic inflammation during midlife and cognitive change over 20 years: The ARIC Study.

Authors:  Keenan A Walker; Rebecca F Gottesman; Aozhou Wu; David S Knopman; Alden L Gross; Thomas H Mosley; Elizabeth Selvin; B Gwen Windham
Journal:  Neurology       Date:  2019-02-13       Impact factor: 9.910

Review 8.  The Potential of 'Omics to Link Lipid Metabolism and Genetic and Comorbidity Risk Factors of Alzheimer's Disease in African Americans.

Authors:  Kaitlyn E Stepler; Renã A S Robinson
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

9.  Association of mid-life serum lipid levels with late-life brain volumes: The atherosclerosis risk in communities neurocognitive study (ARICNCS).

Authors:  Kasra Moazzami; Melinda C Power; Rebecca Gottesman; Thomas Mosley; Pamela L Lutsey; Clifford R Jack; Ron C Hoogeveen; Nancy West; David S Knopman; Alvaro Alonso
Journal:  Neuroimage       Date:  2020-09-01       Impact factor: 6.556

10.  Association between kidney disease measures and intracranial atherosclerosis: The ARIC study.

Authors:  Qing Hao; Rebecca F Gottesman; Ye Qiao; Li Liu; Richa Sharma; Elizabeth Selvin; Kunihiro Matsushita; Josef Coresh; Bruce A Wasserman
Journal:  Neurology       Date:  2020-04-17       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.